This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ripple, G. H. Articles by Bailey, H. H. Search for Related Content PubMed PubMed Citation Articles by Ripple, G. H. Articles by Bailey, H. H.

Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day¹

University of Wisconsin Comprehensive Cancer Center, Developmental Therapeutics Program, Madison, Wisconsin 53792

We conducted a phase I dose-escalation trial of perillyl alcohol (POH; NSC 641066) given p.o. on a continuous four times a day basis to characterize the maximum tolerated dose, toxicities, pharmacokinetic profile, and antitumor activity. Sixteen evaluable patients with advanced refractory malignancies were treated at the following doses: level 1 (L1), 800 mg/m²/dose; L2, 1200 mg/m²/dose; L3, 1600 mg/m²/dose. POH was formulated in soft gelatin capsules containing 250 mg of POH and 250 mg of soybean oil. The predominant toxicities seen were gastrointestinal (nausea, vomiting, satiety, and eructation), which were dose limiting. There appeared to be a dose-dependent increase in levels of the two main metabolites, perillic acid and dihydroperillic acid. No significant differences were seen whether the drug was taken with or without food. There was a trend toward decreasing metabolite levels on day 29 compared with days 1 and 2. Peak metabolite levels were seen 1–3 h post ingestion. Metabolite half-lives were 2 h. Approximately 9% of the total dose was recovered in the urine in the first 24 h, the majority as perillic acid. Evidence of antitumor activity was seen in a patient with metastatic colorectal cancer who has an ongoing near-complete response of >2 years duration. Several other patients were on study for 6 months with stable disease. The maximum tolerated dose of POH given continuously four times a day was 1200 mg/m²/dose. Gastrointestinal toxicity was dose limiting, although significant interpatient variability in drug tolerance was seen.

This article has been cited by other articles:

				H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]

				S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion Clin. Cancer Res., October 1, 2003; 9(12): 4494 - 4504. [Abstract] [Full Text] [PDF]

				D. Rajesh, R. A. Stenzel, and S. P. Howard Perillyl Alcohol as a Radio-/Chemosensitizer in Malignant Glioma J. Biol. Chem., September 19, 2003; 278(38): 35968 - 35978. [Abstract] [Full Text] [PDF]

				B. W. Liston, R. Nines, P. S. Carlton, A. Gupta, R. Aziz, W. Frankel, and G. D. Stoner Perillyl Alcohol as a Chemopreventive Agent in N-Nitrosomethylbenzylamine-induced Rat Esophageal Tumorigenesis Cancer Res., May 15, 2003; 63(10): 2399 - 2403. [Abstract] [Full Text] [PDF]

				D. B. Willis and N. H. Colburn Molecular Targets for Cancer Prevention: A Meeting Review of the Third American Cancer Society-Schilling Research Conference Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 972 - 978. [Abstract] [Full Text] [PDF]

				W. Shi and M. N. Gould Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol Carcinogenesis, January 1, 2002; 23(1): 131 - 142. [Abstract] [Full Text] [PDF]